clinical trial · NCT05332834
A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects
AsthmaSM17Placebo
brief summary
This trial is a phase 1, first-in-human, randomized, double-blind, placebo-controlled dose escalation trial following single and multiple doses intravenous administration of SM17. It aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect and immunogenicity of single and multiple doses of SM17 injection in healthy subjects.
started
Jun 14, 2022
primary completion
Sep 26, 2023
completion
Sep 26, 2023
last updated
Sep 27, 2024
official title
A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SM17 When Administered Intravenously as a Single Ascending Dose in Healthy Subjects (Part A) and as Multiple Ascending Doses in Healthy Subjects (Part B)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol